Journal Articles on Mesothelioma: 'Pleural' Category
Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.
June 24th, 2008. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
Priming of autologous T cells by DCs loaded with MV-infected MPM cells led to a significant proliferation of tumor-specific CD8 T cells. Altogether, these data strongly support the potential of oncolytic MV as an efficient therapeutic agent for mesothelioma cancer.
June 24th, 2008. Asbestos Burden Predicts Survival in Pleural Mesothelioma
Conclusion: Our data suggest that patient survival is associated with asbestos fiber burden in MPM and is perhaps modified by susceptibility.
June 24th, 2008. Chemotherapy of malignant pleural mesothelioma: have we made any progress?
Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients. In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.
June 11th, 2008. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
Posted in Carboplatin, Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Immunohistochemistry or IHC, Occupational Asbestos Exposure, PET Scan, Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment: | No Comments »
June 6th, 2008. Uroplakin is not a Reliable Immunohistochemical Marker for Malignant Mesothelioma of the Pleura
Conclusions: At an antibody dilution for which positive and negative control tissues stain appropriately, PMM does not stain for URO. At higher antibody concentrations, PMM exhibits nonspecific cytoplasmic staining. We assert that URO is not a useful immunohistochemical marker for the detection of PMM. Further studies addressing whether URO is overexpressed at the mRNA level in PMM are warranted.
June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, melphalan, paclitaxel | No Comments »
June 5th, 2008. Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural, Pleural Biopsy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, thoracoscopy | No Comments »
June 4th, 2008. Pulmonary Paragonimiasis with Coincidental Malignant Mesothelioma
Here, we report a very rare case of malignant mesothelioma with a concomitant infection of parasitic lung fluke. Keywords: paragonimiasis, malignant mesothelioma, eosinophilia.
May 20th, 2008. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.
May 20th, 2008. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Interpretation: The addition of chemotherapy to ASC offers no significant benefits in terms of overall survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pleural, Radiation, Survival, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, mitomycin-C | No Comments »
May 16th, 2008. Neoplastic and nonneoplastic conditions of serosal membrane origin: CT findings
Nonneoplastic conditions manifest as focal or diffuse thickening of the serosal membrane, a variable amount of fluid in the serosal cavity, and a soft-tissue mass at CT. Although the CT findings of some of the conditions overlap, knowledge of the typical findings is helpful in narrowing the differential diagnosis.
May 14th, 2008. MR Imaging of Benign and Malignant Pleural Disease
Abstract MR imaging serves as a problem-solving tool in the diagnosis of inflammatory and infectious pleural diseases and primary and secondary pleural malignancies. Knowledge of MR imaging appearance of pleural diseases, including pleural effusions and empyema, benign and malignant pleural tumors, and especially mesothelioma, helps guide treatment decisions and surgical planning.
April 30th, 2008. Malignant mesothelioma with unexpected contralateral mediastinal shift: a case report
Conclusions: This case illustrates mediastinal shift away from the affected side which was caused by mesothelioma tissue itself, rather than by a pleural effusion which is the more usual cause of contralateral mediastinal shift in mesothelioma.
April 30th, 2008. Pleural mesothelioma and venous thrombosis: the eosinophilia link
We describe a patient with mesothelioma who developed peripheral blood eosinophilia followed by deep vein thrombosis despite being on low molecular weight heparin prophylaxis. We discuss the genesis of peripheral blood eosinophilia and thrombosis in pleural mesothelioma.
April 30th, 2008. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma
Conclusions: In malignant pleural mesothelioma, the presence of occult disease in resection margins and lymph nodes can be identified by immunohistochemistry and significantly influences the prognosis. Cervical mediastinoscopy is useful in all patients considered for radical resection, but all specimens should be processed with immunohistochemical staining.
Posted in Biphasic or Mixed, Determining Efficacy, Diagnosis & Differentiation, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Immunohistochemistry or IHC, Pleural, Sarcomatoid, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 30th, 2008. VATS in Diagnostic and Treatment of Malignant Pleural Mesothelioma on the Occasion of Advanced Pleural Mesothelioma
Conclusion: 1.Surgical treatment is decisive for diagnosis and treatment of malignant pleural mesothelioma even in advanced cases and have evident positive effects. 2. Surgical methods improve patient's condition, even in inoperable cases. 3. VATS surgery is modern method for diagnosis and treatment and if it necessary we can continue by conventional operation for definitive treatment of mesothelioma.
Posted in CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Full Archive, General, Pleural, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 25th, 2008. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: Feasibility and responsiveness to clinical changes
Conclusion: The SEIQoL assessment seems to be feasible within a phase II clinical trial, but may require more effort from staff. More distinctive QoL changes in accordance with clinical changes were measured with the RSCL. Our findings suggest that the two measures are not interchangeable: the RSCL is to favor when mainly information related to the course of disease- and treatment is of interest.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Pleural, Pneumonectomy, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 25th, 2008. Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients
Conclusion: The Pem/Cis combination provides promising activity and an acceptable safety profile for chemonaive Japanese MPM patients with the same recommend dosage and schedule used in rest of the world.
April 22nd, 2008. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta-analysis
Conclusions: Measurement of pleural CEA is likely to be a useful diagnostic tool for confirming MPE, and is also helpful in the differential diagnosis between malignant pleural mesothelioma and metastatic lung cancer. The results of CEA assays should be interpreted in parallel with clinical findings and the results of conventional tests.
|
|  |
